Abstract
Introduction
The role of the community pharmacist and the nature of community pharmacy practice have undergone considerable evolution in recent decades as the number of medications consumed in addition to the spending on prescription drugs have markedly increased. Nearly 81 percent of older adults between the ages of 57 and 85 use at least one prescription medication and one in three older adults use at least five or more prescription medications. 1 Spending on prescription drugs has significantly increased from $51 billion in 1993 to an estimated $244.8 billion in 2009. These numbers are expected to increase to $453.7 billion by 2018, despite the current economic recession. 2 During this same period, the level of training and clinical expertise of the pharmacy practitioner has increased substantially with the implementation of a required Doctor of Pharmacy degree. 3 From 2000 to 2009, the percentage of licensed pharmacists with a Doctor of Pharmacy degree has increased from approximately 14 percent to nearly 22 percent. 40 Pharmacists are well-prepared to identify, address and
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2 resolve drug-related problems their patients may be experiencing and can provide patients with important information about adverse drug reactions and adverse drug events. 4 An adverse drug reaction (ADR) is typically defined as "harm directly caused by a drug at normal doses," 5 while an adverse drug event (ADE) is "harm caused by the use of a drug." 5 An example of an ADR could be myopathy from the usage of a statin, while an example of an ADE could be hepatic failure from inappropriate overdosing of an opioid combination product. Together, ADEs and ADRs are estimated to result in more than 100,000 deaths each year, are between the fourth and sixth leading cause of death in the United States, and are estimated to account for nearly 10 percent of all hospital admissions. 6, 7 The cost of drug-related morbidity and mortality creates a significant economic burden, with the cost in the United States health care system estimated to exceed $177 billion each year. 8 ADE/ADRs are reported to be common in the ambulatory population, with many instances resulting in hospitalization. 6, 7, 9 Serious and fatal ADEs reported to the U.S. Food and Drug Administration (FDA) more than doubled from 1998 to 2005; 7 however, ADE/ADRs are underreported. [10] [11] [12] According to a systematic review, incidence of ADE/ADRs are estimated to be 94 percent higher than actually reported. 11 Many of the ADE/ADRs reported tend to be considered serious and/or life-threatening. 7 There is little information available regarding the prevalence and incidence of "tolerable" ADE/ADRs that may reduce patients' quality of life and decrease medication adherence but do not reach a minimum threshold of "reportability."
Previous research has demonstrated pharmacists' ability to reduce ADEs, primarily in the institutional setting. In one study including pharmacists on a pediatric rounds team, 94 percent of ADEs were prevented. 13 Similar results in other studies have substantiated the value of pharmacists in reducing ADEs, mainly in the inpatient setting. [14] [15] [16] [17] [18] [19] [20] [21] [22] In a study by Thomsen and colleagues (2007) , medication errors resulting in preventable ADEs occur in the prescribing and monitoring stage of the medication use process. 23 These studies clearly demonstrate that pharmacists have the capability to effectively influence the incidence of ADE/ADRs. To date, however, the reduction of ADE/ADRs has primarily been accomplished in closely-monitored and controlled patient populations in institutional settings. 4, [14] [15] [16] [17] [18] [19] [20] [21] [22] While this type of patient care is an extremely vital component of the health care system, there is substantial unmet need to monitor patients in the ambulatory population for the existence of ongoing ADE/ADRs. 20 Community pharmacy practice differs substantially from practice in institutional settings, where pharmacists can provide feedback through chart reviews and patient rounds. 4, [14] [15] [16] [17] [18] [19] [20] [21] [22] The current method of classifying, learning, and recalling ADE/ADRs is based on structuring medication knowledge within each particular therapeutic class. This method of organizing medication knowledge by pharmacological or therapeutic classification provides an efficient approach to the prescribing process, since the ADE/ADRs can be analyzed prospectively. Pharmacists can effectively use their knowledge to aid in the prospective evaluation process of proposed prescribing using this framework. [14] [15] [16] [17] [18] [19] [20] [21] [22] However, in the community setting, pharmacists typically deal with prescriptions retrospectively; when problems occur (i.e. are presented with an ADE/ADR), they must work backward to determine which medication from the patient's regimen is responsible. The manner by which drug information has traditionally been organized and taught can make this process cumbersome when done retrospectively.
Rather than using the current approach, which relies on recall of all possible ADE/ADRs for each medication, the development of a classification system based on ADE/ADRs would provide a list of potential "suspect" medications to the pharmacist allowing for more efficient identification of the causal agent and enable them to effectively recall the most frequently occurring side effects, improving patient safety and outcomes.
Objective
The objectives of this study were to identify the 30 most common adverse drug events or reactions (ADE/ADRs) within the top 200 medications: (1) by raw incidence, (2) weighted by prescription volume, (3) and weighted by retail dollars.
Methods
The After the list of ADE/ADRs was compiled and entered into the database for each medication, another list of ADE/ADRs was compiled for each pharmacological class. Common ADE/ADRs which occurred for each medication within the pharmacologic class were identified and sorted within the database. After entry, the resulting ADE/ADR database for a specific pharmacologic class included ADE/ADRs common to all medications of the pharmacologic class as well as those specific to individual medications. 24 The ADE/ADRs associated with amlodipine
were not weighted by retail dollars, as the information was unavailable.
Results
Evaluation of the master list of all ADE/ADRs contained within the top 200 prescription medications resulted in the identification of 9,829 ADE/ADRs. After consolidation of interchangeable terms, 1,477 unique ADE/ADRs remained.
The top five ADE/ADRs (prior to weighting by retail dollars and prescription volume) occurring in top 200 drugs were: 1) nausea, 2) dizziness/vertigo, 3) headache, 4) vomiting, and 5) rash/skin eruption. The top five most common ADE/ADRs weighted by prescription volume were: 1) dizziness/vertigo, 2) headache, 3) nausea, 4) diarrhea/loose stools, and 5) vomiting, After weighting ADE/ADRs by retail dollars, the top five ADE/ADRs were: 1) dizziness/vertigo, 2) fatigue, 3) vomiting, 4) nausea, and 5) headache.
Overall, the top 30 unweighted and weighted ADE/ADR lists were similar, but there were some differences (see Table 2 ).
Results for the top 30 unweighted and weighted by retail dollars ADE/ADR lists included angioedema, fever, and anaphylaxis, but were not reported in the top 30 list weighted by prescription volume. The unweighted list also did not include the ADE/ADRs of angina/chest pain, xerostomia/dry mouth, and taste perversion/dysguesia which were included on lists weighted by retail dollars and prescription volume. Table 2 presents the results of the top 30 ADE/ADRs unweighted, weighted by prescription volume, and weighted by retail dollars. Also, the 30 most common ADE/ADRs weighted by prescription volume were similar for the tabulations including and excluding amlodipine, with only the ranking of ADE/ADRs differing.
Discussion
The intention of this study was to provide preliminary data for the future development of an alternative method that would provide more information regarding the prevalence and aid in identification of unintended consequences (ADE/ADRs) associated with medication utilization. 
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Information regarding the incidence, prevalence, and frequencies of ADE/ADRs for individual medications and placebo was gathered and entered into the database, when available. However, for a number of medications, ADE/ADR incidence and prevalence data was not readily available. Many of those medications for which information was not available included those which have been on the market for a lengthy period of time (e.g., prednisone and amitriptyline). Similarly, information regarding the medication versus placebo ADE/ADR incidence was frequently unavailable. Therefore, our estimates of the most common 30 ADE/ADRs could not be adjusted for actual incidence (e.g. 10 percent incidence of placebo-induced nausea versus 50 percent incidence of medication-induced nausea) due to limitations of the data sources. Further research is needed to determine the actual prevalence of ADE/ADRs for many of these medications in the ambulatory population.
One problem that arose was clinically similar ADE/ADRs with slight differences in terminology. Several ADE/ADRs were grouped (as seen in Table 1 ) using both a primary literature review and pharmacist clinical judgment due to differences in terminology used in the drug information databases. Grouping decisions were determined on the basis of scientific knowledge regarding medications provided by literature and the pharmacists' educational background. In future research other ADE/ADRs groupings could be determined, since many terms describe ADE/ADRs in different ways. However, for purposes of this study, the research team elected to allow the separation of ADE/ADRs unless the definitions were entirely interchangeable according to the primary literature and clinical judgment.
In this study, the number of occurrences of ADE/ADRs was weighted by retail dollars and by prescription volume and compared. The Drug Topics listing of the top 200 medications does contain complete information by retail dollars and prescription volume for both brand and generic name.
25,26,36, 37 Both listings were selected, analyzed, and presented to avoid systematic bias based on cost differences between prescription medications, which could occur if the rankings were based solely on retail dollars. In addition, comparison of the list of ADE/ADRs created using both prescription volume and retail dollars top 200 rankings provided a method for assessing the sensitivity of our methods in creating the ADE/ADR lists. Arguably, our approach to constructing a list of the most common ADE/ADRs should be sufficiently "sensitive" to be able to discern the differences in ADE/ADR incidence in lists generated according to the criteria of prescription volume and of dollar volume, which each of our lists changed according to the different criteria. We consider the difference in ADE/ADR incidence according to prescription volume and retail dollars as evidence for the validity of our method of developing the ADE/ADR list. Pharmacist medication review and counseling have reduced the rate of ADEs, thereby improving patient outcomes, primarily within the inpatient setting. [14] [15] [16] [17] [18] [19] [20] [21] [22] In addition, increased identification of ADE/ADRs and subsequent counseling in the community setting may lead to greater reporting of pertinent ADE/ADRs to the FDA database, which can lead to changes in both practice and regulation that improve patient safety. 10 This project has derived the approximate estimates of the incidence of ADE/ADRs in the ambulatory population based on published literature. We have used the database to estimate that given the opportunity to ask a patient 30 questions related to the 30 most common ADE/ADRs, without any prior knowledge regarding the specific medications the patient is using, we would be able to identify nearly 30 percent of ADE/ADRs. Future research can utilize these lists to create instruments for the top 200 medications that better estimate the true prevalence of ADE/ADRs in the ambulatory patient population, and ultimately, develop tools to improve patient medication safety.
Limitations
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